Adiponectin in Obese Women With T2DN and Effects by RAS Blocker

• Sponsor: Shanghai Jiao Tong University School of Medicine (Other)
• Overall Status: Completed
• CT.gov ID: NCT00561704
• Collaborator: (none)
• Enrollment: 80
• Duration (Months): 6

Study Details

Study Description

Brief Summary

Insulin resistance typically characterizes type 2 diabetes (T2DM) and prediabetic states and is the prominent feature of the metabolic syndrome.Adiponectin plays an important part in glucose metabolism,insulin resistance, the deterioration of renal function.we hypothesize there is a difference serum adiponectin levels between obese and non-obese women with type 2 diabetic nephropathy. Furthermore, these two groups would respond difference to the RAs blocker(Losartan).

Condition or Disease	Intervention/Treatment	Phase
Obese; Type 2 Diabetes; Diabetic Nephropathy; Glucose Metabolism; Angiotensin II Type 1 Receptor Blockers	Drug: losartan	N/A

Detailed Description

it would be a prospective cohort study. According to BMI, all the women, aged>30yr, diagnosed type 2 diabetic nephropathy, chronic kidney disease stage range from 1 to 4, will be divided to two group. Renal function index(included SCr, GFR, et al),glucose metabolism index( fasting glucose, plasma insulin et al),and adiponectin concentration will be observed and recorded. both two groups females will accept the treatment of RAS blocker(losartan, 100mg daily, 6 month). during the study, the above mentioned parameters will also be recorded 3 month intervals. Meanwhile, any side effects would be pay attention.

Study Design

• Study Type: Interventional
• Actual Enrollment: 80 participants
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Adiponectin in Obese Women With T2DN and Effects by RAS Blocker
• Study Start Date: Apr 1, 2007
• Actual Study Completion Date: Oct 1, 2007

Outcome Measures

Primary Outcome Measures

1. GFR, HbA1c and the adiponectin concentration. [6 month]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 30 Years and Older
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Type 2 diabetic nephropathy

• CKD at stage 1~4

Exclusion Criteria:

• Type 1 diabetes or nondiabetic renal disease

• An elevated plasma K level.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Shanghai Jiao Tong University School of Medicine

Investigators

• Principal Investigator: hui min Jin, MD, shanghai No 3 people's hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00561704
• Other Study ID Numbers: ADL
• First Posted: Nov 21, 2007
• Last Update Posted: Nov 21, 2007
• Last Verified: Nov 1, 2007

• Keywords provided by , ,: obese female; Type 2 Diabetes; Diabetic Nephropathy; Glucose Metabolism; Angiotensin II Type 1 Receptor Blockers; Adiponectin
• Additional relevant MeSH terms: Kidney Diseases; Diabetic Nephropathies; Diabetes Mellitus, Type 2; Losartan

Study Results

No Results Posted as of Nov 21, 2007